The Company sold its commercial oncology products in October 2006 and sold its AVINZA® product line in February 2007. The results of operations related to ...
The company sold its commercial oncology products in October last year and its Avinza product line in February 2007. Total revenues from continuing ...
In 2008, Ligand said it expects to receive roughly $20 million in royalty revenue from King Pharmaceuticals (NYSE:KG) for sales of Avinza and potential ...
The Company sold its commercial oncology products in October 2006 and sold its AVINZA(R) product line in February 2007. The results of operations related to ...
The company sold its commercial oncology products in October last year and its Avinza product line in February 2007. Total revenues from continuing ...
Now, turning to the fourth quarter financial results and as a reminder the results of operations related to the sale of our oncology products and AVINZA are ...
all 13 news articles
The Company sold its commercial oncology products in October 2006 and sold its AVINZA® product line in February 2007. The results of operations related to ...
... 452.8 67.3 72.8 Manufacturing Revenue & Royalties (see page 12) 234.8 271.3 5.2 — Amortized Revenue – Adalat®/Avinza® 30.7 4.5 161.4 206.7 Total Product ...
According to the police, Worden was taking an opiate — Avinza, a pain medication that releases continuous doses of morphine — and the depressants Flurazapam ...